Maurizio Simmaco

Full Professor Molecular Biology - Director Diparmet Diagnostic sciences

Sapienza University of Rome
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Year:

2026

Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7

Year:

2026

Collaborators (19)

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

-

ITALY
View details

Valentina Guarneri

Associate Professor

University of Padova

ITALY
View details

Marina BORRO

Associate Professor - Biochemistry

Sapienza University of Rome

ITALY
View details

Umberto Malapelle

-

ITALY
View details

Edoardo Crimini

Medical Oncologist

European Institute of Oncology

ITALY
View details

Giuseppe Tonini

Full Professor of Medical Oncology

Campus Bio Medico University Hospital

ITALY
View details

Giuseppe Giannini

Head, Unit of Advanced Molecular Diagnostic in Oncology

Sapienza University

ITALY
View details

Lucia Del Mastro

dirigente medico

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro

ITALY
View details

Andrea DeCensi

Director

Champalimaud Foundation

PORTUGAL
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Giuseppe Curigliano

European Institute of Oncology

ITALY
View details

Lidia Strigari

Head of Department

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Alberto Zambelli

Associate Professor

University of Milano-Bicocca

ITALY
View details

Paolo Marchetti

Sapienza University of Rome

ITALY
View details

SIMONA PISEGNA

Sapienza University of Rome

ITALY
View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

ITALY
View details

Chiara Cremolini

University Hospital of Pisa

ITALY
View details